Shanghai Lanyi Therapeutics Co., Ltd.
Shanghai Lanyi Therapeutics Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Not yet recruiting | Phase 1 | 2026-09-14 | NCT07818291 | |
| A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis | Embolism and Thrombosis, antiphospholipid syndrome, autoimmune disease, cardiovascular disorder, immune system disorder, thrombotic disease, vascular disorder | Active, not recruiting | Phase 1 | 2026-06-08 | NCT07632976 | |
| A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome | Recruiting | Phase 1 | 2026-05-14 | NCT07256301 |